Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Ezra Cohen

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0658
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms
      NIH/NIDCR R21DE022454Aug 15, 2012 - Jul 31, 2014
      Role: Principal Investigator
      Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
      NIH/NCI R01CA134633May 10, 2009 - May 31, 2022
      Role: Co-Principal Investigator
      Functional Infrared Imaging Predicts Radiation Mucositis
      NIH/NCI R21CA125000Sep 1, 2007 - Aug 31, 2010
      Role: Principal Investigator
      Rapamycin as an Antineoplastic Agent
      NIH/NCI R21CA112951Jun 6, 2005 - May 31, 2008
      Role: Principal Investigator
      Basic Medical Research Training in Oncology
      NIH/NCI T32CA009566Sep 5, 1987 - Jun 30, 2017
      Role: Co-Principal Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Jacobs MT, Ruiz AL, Cohen E. Does chemoselection open the door for immunotherapy? Ann Oncol. 2017 Aug 01; 28(8):1697-1699. PMID: 28541375.
        View in: PubMed
      2. Tota JE, Anderson WF, Coffey C, Califano J, Cozen W, Ferris RL, St John M, Cohen E, Chaturvedi AK. Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. Oral Oncol. 2017 Apr; 67:146-152. PMID: 28351569.
        View in: PubMed
      3. Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen E, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017 May 11; 36(19):2737-2749. PMID: 27991928.
        View in: PubMed
      4. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen E, Varner JA. Corrigendum: PI3K? is a molecular switch that controls immune suppression. Nature. 2016 Dec 14. PMID: 27974794.
        View in: PubMed
      5. Akthar AS, Hellekson CD, Ganai S, Hahn OM, Maggiore RJ, Cohen E, Posner MC, Chmura SJ, Howard AR, Golden DW. Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ. 2016 Nov 21. PMID: 27873183.
        View in: PubMed
      6. Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen E, Tsien RY, Advani SJ. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun. 2016 Oct 04; 7:13019. PMID: 27698471.
        View in: PubMed
      7. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem C, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen E, Varner JA. PI3K? is a molecular switch that controls immune suppression. Nature. 2016 Sep 19. PMID: 27642729.
        View in: PubMed
      8. Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen E, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864. PMID: 27525386.
        View in: PubMed
      9. Brose MS, Cabanillas ME, Cohen E, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82. PMID: 27460442.
        View in: PubMed
      10. Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen E, Haraf DJ, Vokes EE. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Sep 1; 96(1):21-9. PMID: 27511844.
        View in: PubMed
      11. Abbott DM, Cohen E, Sadeghi N, Stein KD, Erb NL. Considering the survivorship care needs of head and neck cancer survivors. Oral Oncol. 2016 Jun; 57:61-2. PMID: 27130576.
        View in: PubMed
      12. Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen E, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Ann Oncol. 2016 Aug; 27(8):1585-93. PMID: 27084954.
        View in: PubMed
      13. Chen P, Mancini M, Sonis ST, Fernandez-Martinez J, Liu J, Cohen E, Toback FG. A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis. PLoS One. 2016; 11(4):e0152995. PMID: 27049860.
        View in: PubMed
      14. Cohen E, LaMonte SJ, Erb NL, Beckman KL, Sadeghi N, Hutcheson KA, Stubblefield MD, Abbott DM, Fisher PS, Stein KD, Lyman GH, Pratt-Chapman ML. American Cancer Society Head and Neck Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016 May; 66(3):203-39. PMID: 27002678.
        View in: PubMed
      15. Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen E, Califano JA, Lippman SM, Luo J, Gutkind JS. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. Oncotarget. 2016 Mar 8; 7(10):10696-709. PMID: 26882569.
        View in: PubMed
      16. Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen E, Vokes EE, Haraf DJ. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 May; 27(5):908-13. PMID: 26884588.
        View in: PubMed
      17. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen E, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb 1; 2(2):209-16. PMID: 26540028.
        View in: PubMed
      18. Boero IJ, Paravati AJ, Xu B, Cohen E, Mell LK, Le QT, Murphy JD. Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol. 2016 Mar 1; 34(7):684-90. PMID: 26729432.
        View in: PubMed
      19. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algül H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Bánhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolomé A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, Bédard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Bénard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Böckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouché M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, Bütikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ceña V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222. PMID: 26799652; PMCID: PMC4835977 [Available on 01/21/17].
      20. Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen E. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23. PMID: 26598548.
        View in: PubMed
      21. Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, Tremblay G, Forsythe A, McIver B, Cohen E. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015; 9:1561-72. PMID: 26604709.
        View in: PubMed
      22. Yeung KT, Cohen E. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clin Cancer Res. 2015 Dec 15; 21(24):5420-6. PMID: 26487760.
        View in: PubMed
      23. Sacco AG, Cohen E. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015 Oct 10; 33(29):3305-13. PMID: 26351341.
        View in: PubMed
      24. O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen E, Fleming GF, Ratain MJ, Maitland ML. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9. PMID: 26199386.
        View in: PubMed
      25. Sasaki MM, Skol AD, Bao R, Rhodes LV, Chambers R, Vokes EE, Cohen E, Onel K. Integrated Genomic Analysis Suggests MLL3 Is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1222-8. PMID: 26014803.
        View in: PubMed
      26. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen E. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):583-94. PMID: 25892145.
        View in: PubMed
      27. Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen E. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res. 2015 May; 3(5):567-74. PMID: 25769300.
        View in: PubMed
      28. Raju SC, Hauff SJ, Lemieux AJ, Orosco RK, Gross AM, Nguyen LT, Savariar E, Moss W, Whitney M, Cohen E, Lippman SM, Tsien RY, Ideker T, Advani SJ, Nguyen QT. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. Oral Oncol. 2015 May; 51(5):470-5. PMID: 25735654.
        View in: PubMed
      29. Price KA, Cohen E. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncol. 2015 May; 51(5):399-408. PMID: 25725588.
        View in: PubMed
      30. Cohen E, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. Reply to s. Chakraborty et Al. J Clin Oncol. 2015 Mar 10; 33(8):968. PMID: 25667282.
        View in: PubMed
      31. Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen E. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Lett. 2015 Apr 10; 359(2):269-74. PMID: 25641339.
        View in: PubMed
      32. Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F, Cohen E. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Target Oncol. 2015 Dec; 10(4):501-8. PMID: 25559287.
        View in: PubMed
      33. Gross AM, Cohen E. Towards a personalized treatment of head and neck cancer. Am Soc Clin Oncol Educ Book. 2015; 35:28-32. PMID: 25993138.
        View in: PubMed
      34. Xu B, Boero IJ, Hwang L, Le QT, Moiseenko V, Sanghvi PR, Cohen E, Mell LK, Murphy JD. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015 Apr 15; 121(8):1303-11. PMID: 25537836.
        View in: PubMed
      35. Simpson DR, Mell LK, Cohen E. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2015 Apr; 51(4):291-8. PMID: 25532816.
        View in: PubMed
      36. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen E, White KP, Vokes EE, Seiwert TY. Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81. PMID: 25492084.
        View in: PubMed
      37. Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen E. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014; 15:469. PMID: 25432788.
        View in: PubMed
      38. Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen E, Seiwert TY, Haraf DJ, Vokes EE. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205. PMID: 25361984.
        View in: PubMed
      39. Tortorici MA, Cohen E, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89. PMID: 25336084.
        View in: PubMed
      40. Cohen E, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1261-70. PMID: 25315258.
        View in: PubMed
      41. Khattri A, Zuo Z, Brägelmann J, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen E, Lingen MW, White KP, Vokes EE, Seiwert TY. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8. PMID: 25255959.
        View in: PubMed
      42. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen E, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. PMID: 25086664.
        View in: PubMed
      43. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen E, Vokes EE, White KP, Hammerman PS. Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2015 Feb 1; 21(3):632-41. PMID: 25056374.
        View in: PubMed
      44. Cohen E, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. J Clin Oncol. 2014 Sep 1; 32(25):2735-43. PMID: 25049329.
        View in: PubMed
      45. Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen E, Stenson K, Weaver DT, Vokes EE. DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. PLoS One. 2014; 9(7):e102112. PMID: 25019640.
        View in: PubMed
      46. Machiels JP, Licitra LF, Haddad RI, Tahara M, Cohen E. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. BMC Cancer. 2014; 14:473. PMID: 24973959.
        View in: PubMed
      47. Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen E. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†. Ann Oncol. 2014 Sep; 25(9):1813-20. PMID: 24928832.
        View in: PubMed
      48. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen E. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 Sep 1; 120(17):2694-703. PMID: 24844950.
        View in: PubMed
      49. Saloura V, Cohen E, Licitra L, Billan S, Dinis J, Lisby S, Gauler TC. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1227-39. PMID: 24714973.
        View in: PubMed
      50. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen E, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. PMID: 24637941.
        View in: PubMed
      51. Kuo WL, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M, Macleod KF, Cohen E. p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One. 2014; 9(3):e90171. PMID: 24599075.
        View in: PubMed
      52. Hollebecque A, Houédé N, Cohen E, Massard C, Italiano A, Westwood P, Bumgardner W, Miller J, Brail LH, Benhadji KA, Soria JC. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar; 50(5):876-84. PMID: 24456794.
        View in: PubMed
      53. Zakeri K, Macewan I, Vazirnia A, Cohen E, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4. PMID: 24134948.
        View in: PubMed
      54. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen E, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46. PMID: 24002501.
        View in: PubMed
      55. Cohen E, Ahmed O, Kocherginsky M, Shustakova G, Kistner-Griffin E, Salama JK, Yefremenko V, Novosad V. Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. Oral Oncol. 2013 Oct; 49(10):1025-31. PMID: 23988569.
        View in: PubMed
      56. Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen E, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70. PMID: 23900000.
        View in: PubMed
      57. Wong SJ, Campbell B, Massey B, Lynch DP, Cohen E, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E. A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. Oral Oncol. 2013 Sep; 49(9):970-6. PMID: 23845699.
        View in: PubMed
      58. Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen E. Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. J Geriatr Oncol. 2013 Oct; 4(4):327-33. PMID: 24472475.
        View in: PubMed
      59. de Souza JA, de Lima Lopes G, Cohen E. Pharmacoeconomic issues in head and neck oncology. Curr Opin Oncol. 2013 May; 25(3):213-7. PMID: 23508082.
        View in: PubMed
      60. Sivasithamparam J, Visk CA, Cohen E, King AC. Modifiable risk behaviors in patients with head and neck cancer. Cancer. 2013 Jul 1; 119(13):2419-26. PMID: 23575663.
        View in: PubMed
      61. Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen E. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 1; 19(11):3059-67. PMID: 23553850.
        View in: PubMed
      62. Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen E, Seiwert TY. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. PMID: 23490885.
        View in: PubMed
      63. Saloura V, Langerman A, Rudra S, Chin R, Cohen E. Multidisciplinary care of the patient with head and neck cancer. Surg Oncol Clin N Am. 2013 Apr; 22(2):179-215. PMID: 23453331.
        View in: PubMed
      64. Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen E. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol. 2013 Jun; 7(3):359-68. PMID: 23200321.
        View in: PubMed
      65. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen E, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76. PMID: 23104721.
        View in: PubMed
      66. Golden DW, Rudra S, Witt ME, Nwizu T, Cohen E, Blair E, Stenson KM, Vokes EE, Haraf DJ. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82. PMID: 23102863.
        View in: PubMed
      67. Nagilla M, Brown RL, Cohen E. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012 Nov; 29(11):925-34. PMID: 23104465.
        View in: PubMed
      68. Haigentz M, Cohen E, Wolf GT, Strojan P, Eisbruch A, Ferlito A. The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2012 Nov; 48(11):1065-7. PMID: 22981388.
        View in: PubMed
      69. Cohen E, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 1; 18(17):4785-93. PMID: 22872575.
        View in: PubMed
      70. Nwizu T, Ghi MG, Cohen E, Paccagnella A. The role of chemotherapy in locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012 Jul; 22(3):198-206. PMID: 22687944.
        View in: PubMed
      71. Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen E, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-30. PMID: 22621836.
        View in: PubMed
      72. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen E. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep; 48(9):887-92. PMID: 22513208.
        View in: PubMed
      73. Cohen E. New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6. PMID: 22706487.
        View in: PubMed
      74. Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P, Cohen E. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Oral Oncol. 2012 Aug; 48(8):723-9. PMID: 22414289.
        View in: PubMed
      75. Price KA, Cohen E. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol. 2012 Mar; 13(1):35-46. PMID: 22252884.
        View in: PubMed
      76. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen E. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43. PMID: 22371453.
        View in: PubMed
      77. Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, Cohen E, Xing HR, Lussier YA. Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol. 2012 Jan; 8(1):e1002350. PMID: 22291585.
        View in: PubMed
      78. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen E. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr 1; 18(7):2056-65. PMID: 22241789.
        View in: PubMed
      79. Ferreira MB, Lima JP, Cohen E. Novel targeted therapies in head and neck cancer. Expert Opin Investig Drugs. 2012 Mar; 21(3):281-95. PMID: 22239178.
        View in: PubMed
      80. Cohen E, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8. PMID: 22100149.
        View in: PubMed
      81. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen E, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 1; 118(11):2962-70. PMID: 22020702.
        View in: PubMed
      82. Ramírez J, Wu K, Janisch L, Karrison T, House LK, Innocenti F, Cohen E, Ratain MJ. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32. PMID: 21861128.
        View in: PubMed
      83. Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen E, Vokes EE, Blair EA. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011; 3:31. PMID: 21791072.
        View in: PubMed
      84. Choe KS, Haraf DJ, Solanki A, Cohen E, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8. PMID: 21671479.
        View in: PubMed
      85. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen E, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 1; 29(19):2660-6. PMID: 21606412.
        View in: PubMed
      86. Perez CA, Santos ES, Arango BA, Raez LE, Cohen E. Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45. PMID: 21544895.
        View in: PubMed
      87. Rini BI, Schiller JH, Fruehauf JP, Cohen E, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011 Jun 1; 17(11):3841-9. PMID: 21531811.
        View in: PubMed
      88. Gangadhar TC, Cohen E, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, Fleming GF, Ratain MJ. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 1; 17(7):1956-63. PMID: 21447721.
        View in: PubMed
      89. Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, Jones RB, Rosner MR, Cohen E. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82. PMID: 21438065.
        View in: PubMed
      90. Cohen E, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9. PMID: 21439817.
        View in: PubMed
      91. Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen E. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-7. PMID: 21385883.
        View in: PubMed
      92. Langerman A, Patel RM, Cohen E, Blair EA, Stenson KM. Airway management before chemoradiation for advanced head and neck cancer. Head Neck. 2012 Feb; 34(2):254-9. PMID: 21384461.
        View in: PubMed
      93. Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen E, Seiwert T, Vokes EE. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9. PMID: 21330337.
        View in: PubMed
      94. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen E, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72. PMID: 21497773.
        View in: PubMed
      95. Mouw KW, Haraf DJ, Stenson KM, Cohen E, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34. PMID: 21173372.
        View in: PubMed
      96. Choe KS, Salama JK, Stenson KM, Blair EA, Witt ME, Cohen E, Haraf DJ, Vokes EE. Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21. PMID: 20934766.
        View in: PubMed
      97. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, Cohen E. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24. PMID: 20876745.
        View in: PubMed
      98. de Souza JA, Cohen E. [18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality. J Clin Oncol. 2010 Oct 1; 28(28):e516; author reply e517. PMID: 20606097.
        View in: PubMed
      99. Cohen E, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43. PMID: 20498391.
        View in: PubMed
      100. Chen LF, Cohen E, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010 May 1; 16(9):2489-95. PMID: 20406834.
        View in: PubMed
      101. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen E, Louis DN, Settleman J, Haber DA. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64. PMID: 20215515.
        View in: PubMed
      102. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen E. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb; 19(2):358-65. PMID: 20086114; NIHMSID: NIHMS177322.
        View in: PubMed
      103. Stenson KM, Kunnavakkam R, Cohen E, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9. PMID: 19856305.
        View in: PubMed
      104. Mell LK, Dignam JJ, Salama JK, Cohen E, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 1; 28(1):15-20. PMID: 19933920.
        View in: PubMed
      105. de Souza JA, Cohen E. Personalizing cancer care: updates on head and neck cancer. Expert Rev Anticancer Ther. 2009 Sep; 9(9):1219-22. PMID: 19761425.
        View in: PubMed
      106. Choong NW, Kozloff M, Taber D, Hu HS, Wade J, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen E. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010 Oct; 28(5):677-83. PMID: 19649772.
        View in: PubMed
      107. Cohen E, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21. PMID: 19340870.
        View in: PubMed
      108. Cooper JB, Cohen E. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck. 2009 Aug; 31(8):1086-94. PMID: 19378324.
        View in: PubMed
      109. Vidal L, Tsao MS, Pond GR, Cohen E, Cohen RB, Chen EX, Agulnik M, Hotte S, Winquist E, Laurie S, Hayes DN, Ho J, Dancey J, Siu LL. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck. 2009 Aug; 31(8):1006-12. PMID: 19309723.
        View in: PubMed
      110. Cohen E, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009 Oct; 45(10):e155-60. PMID: 19586795.
        View in: PubMed
      111. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen E, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 1; 69(7):3021-31. PMID: 19318576.
        View in: PubMed
      112. Stewart JS, Cohen E, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71. PMID: 19289630.
        View in: PubMed
      113. Cohen E, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57. PMID: 19201650.
        View in: PubMed
      114. Cohen E, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 1; 69(1):65-74. PMID: 19117988.
        View in: PubMed
      115. Kocherginsky M, Cohen E, Karrison T. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. J Biopharm Stat. 2009; 19(3):524-9. PMID: 19384693.
        View in: PubMed
      116. Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen E, Blair E, Vokes EE, Haraf DJ. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5. PMID: 18936351.
        View in: PubMed
      117. Cohn AB, Lang PO, Agarwal JP, Peng SL, Alizadeh K, Stenson KM, Haraf DJ, Cohen E, Vokes EE, Gottlieb LJ. Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-32. PMID: 18594395.
        View in: PubMed
      118. Cohen E, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13. PMID: 18541897.
        View in: PubMed
      119. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen E, Haraf DJ, Vokes EE. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94. PMID: 18539617.
        View in: PubMed
      120. Seiwert TY, Cohen E. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008 Jun; 35(3):274-85. PMID: 18544442.
        View in: PubMed
      121. Mauer AM, Cohen E, Ma PC, Kozloff MF, Schwartzberg L, Coates AI, Qian J, Hagey AE, Gordon GB. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun; 3(6):631-6. PMID: 18520803.
        View in: PubMed
      122. Vokes EE, Cohen E, Grandis JR. Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7. PMID: 18544434.
        View in: PubMed
      123. Knab BR, Salama JK, Solanki A, Stenson KM, Cohen E, Witt ME, Haraf DJ, Vokes EE. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4. PMID: 18467314.
        View in: PubMed
      124. Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, Delgado J, Tretiakova M, Joseph L, Hart J, Cohen E, Aluri L, Fichera A, Bissonnette M. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res. 2008 Apr 15; 14(8):2253-62. PMID: 18413814.
        View in: PubMed
      125. Seiwert TY, Haraf DJ, Cohen E, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 1; 26(10):1732-41. PMID: 18375903.
        View in: PubMed
      126. Cohen E. mTOR: the mammalian target of replication. J Clin Oncol. 2008 Jan 20; 26(3):348-9. PMID: 18202406.
        View in: PubMed
      127. Ahmed SM, Cohen E. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets. 2007 Nov; 7(7):666-73. PMID: 18045071.
        View in: PubMed
      128. Yount S, List M, Du H, Yost K, Bode R, Brockstein B, Argiris A, Vokes E, Cohen E, Campbell B, Valenzuela V, George J, Egan R, Chen J, Meddis D, Cella D. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26. PMID: 17922221.
        View in: PubMed
      129. Seiwert TY, Cohen E, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44. PMID: 17882655.
        View in: PubMed
      130. Cohen E. A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007 Aug 1; 13(15 Pt 1):4317-9. PMID: 17671110.
        View in: PubMed
      131. Ratain MJ, Cohen E. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007 Aug 10; 25(23):3397-8. PMID: 17635950.
        View in: PubMed
      132. Cohen E, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 1; 67(3):678-84. PMID: 17293229.
        View in: PubMed
      133. Cohen E, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44. PMID: 16849759.
        View in: PubMed
      134. Cohen E, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303. PMID: 16778206.
        View in: PubMed
      135. Cohen E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006 Jun 10; 24(17):2659-65. PMID: 16763280.
        View in: PubMed
      136. Ganti AK, Cohen E. Iodine-refractory thyroid carcinoma. Rev Recent Clin Trials. 2006 May; 1(2):133-41. PMID: 18473964.
        View in: PubMed
      137. Stenson KM, Huo D, Blair E, Cohen E, Argiris A, Haraf DJ, Vokes EE. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6. PMID: 16481805.
        View in: PubMed
      138. Cohen E, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 1; 11(23):8418-24. PMID: 16322304.
        View in: PubMed
      139. Cohen E, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. PMID: 16299242.
        View in: PubMed
      140. Choong NW, Cohen E. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006 Jan; 57(1):25-43. PMID: 16207530.
        View in: PubMed
      141. Seiwert TY, Cohen E. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 2005 Apr 25; 92(8):1341-8. PMID: 15846296.
        View in: PubMed
      142. Cohen E. Novel therapeutic targets in squamous cell carcinoma of the head and neck. Semin Oncol. 2004 Dec; 31(6):755-68. PMID: 15599853.
        View in: PubMed
      143. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen E, Vokes EE, Weichselbaum RR. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83. PMID: 15547705.
        View in: PubMed
      144. Cohen E, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 1; 22(9):1743-52. PMID: 15117998.
        View in: PubMed
      145. Cohen E, Vokes EE. Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):81-90. PMID: 15005282.
        View in: PubMed
      146. Rudin CM, Cohen E, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15; 21(24):4546-52. PMID: 14597742.
        View in: PubMed
      147. Cohen E, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15; 21(10):1980-7. PMID: 12743152.
        View in: PubMed
      148. Hoffman PC, Cohen E, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71. PMID: 12367795.
        View in: PubMed
      149. Cohen E, Vokes EE. Searching for a standard. J Clin Oncol. 2002 Jan 15; 20(2):359-61. PMID: 11786560.
        View in: PubMed
      150. Cohen E, Vokes EE. Esophageal cancer therapy: a decade of inertia. Cancer J. 2001 Sep-Oct; 7(5):369-71. PMID: 11693893.
        View in: PubMed
      151. Cohen E, Vokes EE. Locally advanced non-small cell lung cancer. Curr Treat Options Oncol. 2001 Feb; 2(1):27-42. PMID: 12057138.
        View in: PubMed